BlackRock Fund Advisors raised its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 6.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,611,265 shares of the company’s stock after buying an additional 168,773 shares during the period. BlackRock Fund Advisors owned about 7.19% of Omnicell worth $100,011,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Victory Capital Management Inc. increased its position in shares of Omnicell by 77.2% in the second quarter. Victory Capital Management Inc. now owns 3,069 shares of the company’s stock worth $105,000 after buying an additional 1,337 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Omnicell by 605.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,374 shares of the company’s stock worth $150,000 after buying an additional 3,754 shares in the last quarter. PineBridge Investments L.P. increased its position in shares of Omnicell by 4.0% in the second quarter. PineBridge Investments L.P. now owns 4,555 shares of the company’s stock worth $156,000 after buying an additional 177 shares in the last quarter. Sei Investments Co. increased its position in shares of Omnicell by 165.3% in the third quarter. Sei Investments Co. now owns 4,229 shares of the company’s stock worth $162,000 after buying an additional 2,635 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its position in shares of Omnicell by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 4,957 shares of the company’s stock worth $170,000 after buying an additional 600 shares in the last quarter. 93.82% of the stock is currently owned by institutional investors.
Omnicell, Inc. (NASDAQ:OMCL) opened at 32.15 on Tuesday. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of 147.48 and a beta of 0.69. The stock has a 50 day moving average price of $34.20 and a 200 day moving average price of $35.65. Omnicell, Inc. has a 12-month low of $25.06 and a 12-month high of $40.50.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, October 27th. The company reported $0.40 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.41 by $0.01. Omnicell had a return on equity of 10.74% and a net margin of 1.24%. The company earned $179.40 million during the quarter, compared to analysts’ expectations of $179.75 million. During the same quarter last year, the business earned $0.36 earnings per share. The business’s quarterly revenue was up 43.3% on a year-over-year basis. On average, analysts expect that Omnicell, Inc. will post $1.55 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Omnicell, Inc. (OMCL) Position Raised by BlackRock Fund Advisors” was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be accessed at https://www.com-unik.info/2017/01/10/omnicell-inc-omcl-position-raised-by-blackrock-fund-advisors.html.
OMCL has been the topic of a number of recent analyst reports. Oppenheimer Holdings, Inc. set a $46.00 price objective on Omnicell and gave the company a “buy” rating in a research note on Thursday, October 27th. Benchmark Co. boosted their target price on Omnicell from $39.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, December 6th. TheStreet lowered Omnicell from a “buy” rating to a “hold” rating in a research report on Friday, November 11th. Finally, Cantor Fitzgerald started coverage on Omnicell in a research report on Thursday, January 5th. They issued an “overweight” rating and a $40.00 target price for the company. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $42.25.
In other news, VP J Christopher Drew sold 20,000 shares of Omnicell stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $31.95, for a total transaction of $639,000.00. Following the completion of the transaction, the vice president now directly owns 139,844 shares in the company, valued at $4,468,015.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jorge R. Taborga sold 2,068 shares of Omnicell stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $33.66, for a total transaction of $69,608.88. Following the transaction, the vice president now owns 47,223 shares of the company’s stock, valued at $1,589,526.18. The disclosure for this sale can be found here. 3.75% of the stock is currently owned by company insiders.
Omnicell Company Profile
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.
What are top analysts saying about Omnicell Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Omnicell Inc. and related companies.